Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.

Abstract

This small-scale prospective study investigated the changes in antigen-specific IgG4 (sIgG4) that occur during long-term dupilumab treatment in patients with atopic dermatitis. While dupilumab has been reported to have an inhibitory effect on B-cell maturation, the increase in sIgG4 during dupilumab treatment may indicate that dupilumab indirectly improves allergies in those predisposed to them. We present the possibility of a new therapeutic effect of long-term dupilumab use.